Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Date:10/30/2007

sident and chief

executive officer of Gilead Sciences, Inc., has been elected to its

board of directors. Gen-Probe's board now has eight members,

including seven who are not Gen-Probe employees.

-- Update on PROCLEIX ULTRIO Post-Marketing Study. To date,

participating blood banks have screened approximately 260,000 blood

donations in the post-marketing study for the PROCLEIX ULTRIO assay,

which is designed to demonstrate hepatitis B virus (HBV) "yield."

Yield is defined as HBV-infected blood donations that were intercepted

by the PROCLEIX ULTRIO assay, but that were initially negative based

on traditional serology tests. Gen-Probe believes that the first of

two required yield cases has been identified in the study, although

this must be confirmed through a regulatory submission to the FDA.

The FDA has approved the PROCLEIX ULTRIO assay to screen donated blood

for HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as

the initial clinical studies were not designed to, and did not,

demonstrate HBV yield. Gen-Probe and Novartis are conducting the

post-marketing study to demonstrate HBV yield and gain the associated

donor screening claim.

Webcast Conference Call

A live webcast of Gen-Probe's third quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 947-6450 for domestic callers and (203) 369-3539 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic aci
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... health and nutritional food industry,engaged in the development, ... and raw cactus plants in the People,s,Republic of ... Mr. Ren,Hu will present at the upcoming Roth ...
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... in medicine. Although no significant achievements for curing disease have been achieved, ... approaches. By the year 2015, global market for gene therapy is projected ... ... 2008 -- Advancements in gene therapy have provided useful data, which has ...
Cached Biology Technology:China Yingxia to Present at Roth China Comes to Vegas Conference 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
... Minnesota finalized a license agreement for CaSTT (Commerce and ... for technology transfer offices in universities and research institutions. ... consulting services that allow technology transfer offices to make ... and, in some cases, execute licenses from start to ...
Cached Biology News:Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2